Record numbers attend OBN’s BioTrinity conference: Catalysing Growth in the Life Science Industry

Oxford and London, UK, 28 April 2023: OBN (UK) Ltd., the membership organisation whose mission is to catalyse growth in the life sciences industry, announces that its annual BioTrinity conference, held this week in London, was attended by record numbers of life sciences delegates and included 1,500 partnering meetings designed to fuel deal-making in the sector.

BioTrinity ’23 comprised a two-day in-person event and a third virtual partnering day, offering delegates from innovative life sciences companies, investors, pharma companies, science parks and professional services organisations the opportunity to network, connect and build partnerships to drive sector growth. 

Parallel science and business tracks gave delegates a choice of content, with highlights including oncology, neuroscience, cell & gene therapy and quantum computing, as well as the importance of ESG and EDI, the future role of the CEO, some reflections from inspiring female leaders and a review of the investment environment including a glimpse of what the future may hold.

"We are delighted with the success of this year's BioTrinity conference," said Stuart Rose, OBN’s CEO. “2022 was a challenging time for the sector but there’s a real sense of optimism for what is to come. Perhaps more than many other sectors, life sciences is resilient and, when faced with challenge, ever more innovative. We may be approaching the nadir in the industry and the technologies and leadership teams that emerge from this time will be poised to achieve great things that lead to real healthcare gains over the next decade. OBN is pleased to be able to play a part in catalysing some of this success through events such as BioTrinity.”

For more information about OBN, please visit www.obn.org.uk 

Follow OBN on LinkedIn (OBN UK) for updates on this event, and more.

ENDS